PMV Pharmaceuticals, Inc.
PMVP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001699382
No open-market purchases or sales by PMV Pharmaceuticals, Inc. insiders were filed in the last 90 days; 64 institutions reported holding it in 13F filings for Q2 2026, worth $46.4M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −5 vs. previous quarter
- 64
- 13F valueReported value at the end of Q2 2026
- $46.4M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding PMVP, Q2 2026
No superinvestor reported holding PMVP at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by PMV Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 27, 2025 (view filing)5:19 PM ET | Oct 23 | 4 days | OrbiMed Advisors LLC and 1 other10% Owner | SSale | −1.00M | $1.52 | −$1.52M | −16.7%4.98M after | |
| Sep 12, 2025 (view filing)5:09 PM ET | Sep 10 | 2 days | OrbiMed Advisors LLC and 1 other10% Owner | SSale | −500.0K | $1.80 | −$900.0K | −7.7%5.98M after | |
| Jul 3, 2025 (view filing) | Jul 1 | 2 days | Ticktin RobertGeneral Counsel & COO | SSale | −23.2K | $1.06 | −$24.5K | −19.0%98.7K after | |
| Jul 3, 2025 (view filing) | Jul 1 | 2 days | Jalota DeepikaChief Development Officer | SSale | −33.1K | $1.06 | −$35.0K | −26.9%90.0K after | |
| Jul 3, 2025 (view filing) | Jul 1 | 2 days | Carulli MichaelChief Financial Officer | SSale | −28.2K | $1.06 | −$29.9K | −32.0%60.1K after | |
| Jul 3, 2025 (view filing) | Jul 1 | 2 days | Mack David HenryPresident and CEO | SSale | −58.4K | $1.06 | −$61.9K | −9.8%536.1K after | |
| Sep 12, 2024 (view filing) | Sep 11 | 1 day | Jalota DeepikaChief Development Officer | SSale | −7.22K | $1.50 | −$10.8K | −5.8%118.3K after | |
| Sep 12, 2024 (view filing) | Sep 11 | 1 day | Carulli MichaelChief Financial Officer | SSale | −2.89K | $1.50 | −$4.34K | −3.2%88.4K after | |
| Nov 24, 2023 (view filing)4:38 PM ET | Nov 22 | 2 days | OrbiMed Advisors LLC and 2 others10% Owner | SSale | −87.8K | $2.23 | −$195.8K | −100.0%0 after | |
| Sep 18, 2023 (view filing) | Sep 15 | 3 days | Jalota DeepikaChief Development Officer | SSale | −4.10K | $6.62 | −$27.2K | −12.1%29.9K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in PMV Pharmaceuticals, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BML Capital Management, LLC | 5,330,000 | $7.14M | 4.08% | +10,000+0.2% | Added |
| Tang Capital Management LLC | 4,245,085 | $5.69M | 0.26% | 00.0% | Unchanged |
| Sio Capital Management, LLC | 2,634,137 | $3.53M | 0.60% | −442,443−14.4% | Reduced |
| Euclidean Capital LLC | 2,627,643 | $3.52M | 0.80% | 00.0% | Unchanged |
| Adage Capital Partners GP, L.L.C. | 2,360,000 | $3.16M | 0.00% | +500,000+26.9% | Added |
| Acadian Asset Management LLC | 2,215,894 | $2.97M | 0.00% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 2,012,020 | $2.70M | 0.00% | +37,114+1.9% | Added |
| ArrowMark Colorado Holdings LLC | 1,959,579 | $2.63M | 0.11% | −913,185−31.8% | Reduced |
| Two Sigma Investments, LP | 1,954,136 | $2.62M | 0.00% | +69,606+3.7% | Added |
| Eversept Partners, LP | 1,890,904 | $2.53M | 0.14% | −457,456−19.5% | Reduced |